ReviewInternational journal of molecular sciences2018
The Janus Face of NKT Cell Function in Autoimmunity and Infectious Diseases.
Review in International journal of molecular sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 44 citations in OpenAlex.
- Pentraxin 3 and the TyG Index as Two Novel Markers to Diagnose NAFLD in Children.Disease markers · 2021Trial
- Nonclassical MHC-I Molecules: Emerging Therapeutic Targets in Next-Generation Immunotherapy.MedComm · 2026Review
- Identification of Key Genes and Exploration of Therapeutic Targets for Chronic Tendon Injury Based on Bioinformatics and Machine Learning.International journal of general medicine · 2026Article
- Machine Learning Reveals the Value of Unconventional T Lymphocytes in Sepsis and Prognosis of Elderly Patients With Severe Lower Respiratory Tract Infections.Journal of clinical laboratory analysis · 2025Article
- NKT cells-a generalist in disease treatment and a new key to unlock immunotherapy.Immunotherapy · 2025Review
- Immunological landscape of children with Mycoplasma pneumoniae pneumonia in the post-COVID-19 era reveals distinctive severity indicators.Respiratory research · 2025Article
- CD3Frontiers in immunology · 2025Review
- The Emerging Roles and Therapeutic Potential of Unconventional T Cells in Sepsis.Journal of inflammation research · 2025Review
- Analysis and experimental validation of IL-17 pathway and key genes as central roles associated with inflammation in hepatic ischemia-reperfusion injury.Scientific reports · 2024Article
- Severity of critical illness correlates with CD3-low expression on iNKT-cells among septic surgical patients.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024Article
- Deficiency and dysfunctional roles of natural killer T cells in patients with ARDS.Frontiers in immunology · 2024Article
- Phosphatidylinositolmannoside vaccination induces lipid-specific Th1-responses and partially protects guinea pigs from Mycobacterium tuberculosis challenge.Scientific reports · 2023Article
- Decreased natural killer T-like cells correlated to disease activity in systemic lupus erythematosus.Clinical rheumatology · 2023Article
- Natural Killer T-like Cells: Immunobiology and Role in Disease.International journal of molecular sciences · 2023Review
- The paradigm of IL-23-independent production of IL-17F and IL-17A and their role in chronic inflammatory diseases.Frontiers in immunology · 2023Review
- An Overview: Genetic Tumor Markers for Early Detection and Current Gene Therapy Strategies.Cancer informatics · 2023Review
- Increased Pro Th1 And Th17 Transcriptional Activity In Patients With Severe COVID-19.International journal of medical sciences · 2023Article
- Single-cell analysis reveals differences among iNKT cells colonizing peripheral organs and identifies Klf2 as a key gene for iNKT emigration.Cell discovery · 2022Article
- Diminished natural killer T-like cells correlates with aggravated primary Sjögren's syndrome.Clinical rheumatology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural killer T cells (NKT) are a subset of T lymphocytes bridging innate and adaptive immunity. These cells recognize self and microbial glycolipids bound to non-polymorphic and highly conserved CD1d molecules. Three NKT cell subsets, type I, II, and NKT-like expressing different antigen receptors (TCR) were described and TCR activation promotes intracellular events leading to specific functional activities. NKT can exhibit different functions depending on the secretion of soluble molecules and the interaction with other cell types. NKT cells act as regulatory cells in the defense against infections but, on the other hand, their effector functions can be involved in the pathogenesis of several inflammatory disorders due to their exposure to different microbial or self-antigens, respectively. A deep understanding of the biology and functions of type I, II, and NKT-like cells as well as their interplay with cell types acting in innate (neuthrophils, innate lymphoid cells, machrophages, and dendritic cells) and adaptive immunity (CD4⁺,CD8⁺, and double negative T cells) should be important to design potential immunotherapies for infectious and autoimmune diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.